Oxford Drug Design and PhoreMost collaborate to advance novel cancer therapeutics discovery
Oxford Drug Design, a biotechnology company with core expertise in computer-aided drug design, has announced that it has been engaged by PhoreMost Ltd (PhoreMost), a UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, to accelerate a targeted protein degradation discovery programme for novel cancer therapeutics.
The project leverages Oxford Drug Design’s proprietary artificial intelligence (AI) computational platform consisting of multiple computational drug discovery capabilities for both ligand- and structure-based design, together with PhoreMost’s next-generation SITESEEKER® phenotypic screening platform and PROTEINi® libraries. In doing so, Oxford Drug Design has analyzed the structural biology data and known binding compounds to identify and advance the development of novel, drug-like, compounds for onward optimization.
The global AI drug discovery market is estimated to be worth $5 billion by 2027, according to a recent report by MarketsandMarkets. With traditional drug discovery being a costly and lengthy process, the highly distinctive AI and machine learning technologies developed by Oxford Drug Design offer the prospect of analyzing vast datasets and developing viable drugs in an automated and more cost-efficient way.
---
About Oxford Drug Design Ltd
Oxford Drug Design, a pre-clinical stage therapeutics spinout from Oxford University, is discovering innovative anti-cancer therapeutics supported by pioneering computational methods. At the cutting edge of machine learning and AI applied to pre-clinical drug discovery, Oxford Drug Design is also expanding to provide its proprietary computational capabilities to third parties to advance their internal programmes.
